MYDGF overexpression upregulates isocitrate dehydrogenase 2 (IDH2), restores mitochondrial homeostasis, and slows CKD progression, suggesting that MYDGF is an attractive therapeutic target for CKD. Here, IDH2 is linked to chronic kidney disease.